Updates from ESMO 2022 - Metastatic Breast Cancer Trial Talk

Conference Talk

The European Society for Medical Oncology (ESMO) held its annual meeting from September 9-13, 2022 in Paris, France and virtually. Click the links below for MBC-related highlights of this meeting.

Sacituzumab Govitecan (Trodelvy®) for Hormone Receptor-Positive, HER2-Negative MBC
Metronomic Chemotherapy for Estrogen Receptor-Positive, HER2-Negative MBC
Ribociclib (Kisqali®) Plus Endocrine Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
 Quality of Life with Trastuzumab Deruxtecan (Enhertu®)



for past articles or specific information.